Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare cancers and viral infections. This dedicated news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access real-time information about Chimerix's innovative pipeline, including its lead candidate dordaviprone for H3 K27M-mutant glioma and ongoing research in antiviral treatments. The curated collection features press releases, financial reports, and scientific presentations – all vital for understanding the company's progress in addressing unmet medical needs.
Key content categories include clinical trial results, FDA communications, partnership announcements, and financial performance updates. Each update is carefully verified to ensure accuracy and relevance for stakeholders monitoring therapeutic advancements in oncology and infectious diseases.
Bookmark this page for streamlined access to Chimerix's latest developments. Check regularly for critical updates on drug approvals, research breakthroughs, and strategic initiatives that shape the company's trajectory in biopharmaceutical innovation.
Chimerix, a biopharmaceutical company, has successfully closed its public offering of common stock, selling 13,529,750 shares at $8.50 each, yielding gross proceeds of $115 million. This follows the underwriters' full exercise of their option to purchase additional shares. The net proceeds will be allocated to fund clinical development of product candidates, pre-launch activities, and general corporate purposes. Jefferies and Cowen served as joint bookrunners for the offering. The securities were offered under an effective SEC registration statement.
Chimerix, a biopharmaceutical company (Nasdaq: CMRX), has priced its public offering of 11,765,000 shares at $8.50 each, aiming to raise approximately $100 million before expenses. This offering, expected to close around January 25, 2021, has an additional 30-day option for underwriters to purchase up to 1,764,750 shares. Proceeds will fund clinical developments, commercial activities, and general expenses. Jefferies and Cowen are leading this offering, with securities filed under SEC registration. Chimerix focuses on innovative treatments for cancer and serious diseases.
Chimerix, Inc. (Nasdaq: CMRX) has announced plans to offer up to $75 million in common stock through an underwritten public offering, with an additional $11.25 million option for underwriters. Proceeds will fund clinical development, commercial pre-launch activities, and general corporate purposes. Jefferies and Cowen are managing the offering. The offering is subject to market conditions and is made under a previously filed shelf registration statement with the SEC. Completion timing and terms remain uncertain.
Chimerix (NASDAQ:CMRX) has announced the acquisition of Oncoceutics, a privately-held company developing ONC201, a promising therapy for recurrent H3 K27M-mutant glioma. This acquisition, costing $78 million, positions Chimerix to advance its oncology portfolio, with ONC201 showing a compelling overall response rate of at least 20% in early trials. A regulatory pathway for potential approval is outlined, addressing a market opportunity exceeding $500 million. Upcoming milestones include a confirmatory data analysis expected in 2021 and a PDUFA date for another treatment in April.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced CEO Mike Sherman will present at the H.C. Wainwright BioConnect 2021 Conference, available on January 11, 2021, at 7:00 a.m. ET. This pre-recorded presentation will be accessible via the Investor Relations section of Chimerix's website for 90 days.
Chimerix is focused on developing medicines for serious diseases, with key programs including dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is in trials for acute lung injury related to COVID-19 and acute myeloid leukemia, while BCV seeks regulatory approval as a smallpox countermeasure.
Chimerix (NASDAQ:CMRX) announced that the FDA has accepted the New Drug Application (NDA) for brincidofovir (BCV) as a countermeasure for smallpox. The FDA granted Priority Review status, aiming for a decision by April 7, 2021. BCV has shown antiviral activity against smallpox in animal studies and is backed by funding from BARDA. The Priority Review designation reduces the review time from 10 months to a target of 6 months, suggesting the treatment may significantly improve safety or effectiveness for this serious condition.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Credit Suisse 29th Annual Healthcare Conference on November 12, 2020, at 4:15 p.m. ET. This event will be available via live audio webcast on Chimerix's Investor Relations website and archived for 90 days. The company is advancing innovative medicines for cancer and serious diseases, focusing on two clinical-stage programs: dociparstat sodium (DSTAT) and brincidofovir (BCV), with DSTAT currently in trials for COVID-19 and acute myeloid leukemia.
Chimerix (CMRX) achieved major milestones in Q3 2020, including completing NDA submissions for brincidofovir (BCV) as a smallpox countermeasure. The company anticipates FDA notification regarding submission acceptance and a PDUFA date by year-end. Expected milestones include initiating a Phase 3 AML trial in early 2021 and a potential procurement contract with BARDA. Financially, Chimerix reported a net loss of $11.4 million, improved from $73.7 million in Q3 2019, with revenues of $1.6 million, down from $2.0 million. The company maintains a healthy balance sheet with $87.8 million available.
Chimerix (CMRX) will host a conference call on November 5, 2020, at 8:30 a.m. ET to report Q3 2020 financial results and provide a business overview. The company focuses on innovative medicines for cancer and serious diseases, with key products including dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is under Phase 2/3 trials for COVID-19 related acute lung injury and has an agreed Phase 3 protocol for acute myeloid leukemia. Stakeholders can access the call via phone or webcast, with details available on the company's website.
Chimerix (NASDAQ: CMRX), a biopharmaceutical firm, announced its participation in two investor conferences in September. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 1:00 p.m. ET, where Chimerix will present a corporate overview and hold investor meetings. Additionally, management will engage in investor meetings at the Cantor Fitzgerald Virtual Healthcare Conference on September 16. A live audio webcast of the presentation will be available on their Investor Relations website.
Chimerix focuses on developing innovative treatments, including DSTAT for acute lung injury and BCV as a countermeasure for smallpox.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
